In 99 patients after curative-intent surgery for 4 or more colorectal liver metastases, adjuvant hepatic arterial infusion oxaliplatin vs IV oxaliplatin (both with LV5FU2) improved median hepatic RFS (25 vs 12 months; HR 0.63); grade 3-4 adverse events 58% vs 32%.
RCTn = 99
Gelli et al. Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial